Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Baxter
Moodys

Last Updated: August 8, 2022

Investigational Drug Information for Ifetroban


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Ifetroban?

Ifetroban is an investigational drug.

There have been 9 clinical trials for Ifetroban. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2011.

The most common disease conditions in clinical trials are Respiratory Tract Diseases, Respiration Disorders, and Hypertension. The leading clinical trial sponsors are Cumberland Pharmaceuticals, Jeffrey Rade, and Brigham and Women's Hospital.

Recent Clinical Trials for Ifetroban
TitleSponsorPhase
Oral Ifetroban in Subjects With Duchenne Muscular DystrophyVanderbilt University Medical CenterPhase 2
Oral Ifetroban in Subjects With Duchenne Muscular DystrophyCumberland PharmaceuticalsPhase 2
Thromboxane Receptor Antagonist to Improve Endothelial Cell FunctionAmerican Heart AssociationPhase 2

See all Ifetroban clinical trials

Clinical Trial Summary for Ifetroban

Top disease conditions for Ifetroban
Top clinical trial sponsors for Ifetroban

See all Ifetroban clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.